IKT-903

N/A

Report date: 2026/03/19 16:58:12

Base Information

Drug NameIKT-903
Drug Alias Nameanti-CD3/anti-EphA2 bispecific T-cell engager (Icell Kealex)EphA2-TEA-VVIKT-903
ClassificationBiologics > Oncolytic virusBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsEphrin type-A receptor 2 modulators
TargetsEphrin type-A receptor 2T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesIcell Kealex TherapeuticsBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A